FDA Approves First On-Body Injectable for Multiple Myeloma, Sanofi's Sarclisa Escena
SNY is trading near its 52-week low of $40.89 (6.8% above the low).
Summary
The FDA approved Sanofi's subcutaneous Sarclisa Escena with the CirCLIQ on-body injector for all existing IV indications in multiple myeloma. This is the first anticancer treatment delivered via an on-body injector, offering a significantly shorter administration time and fewer infusion-related reactions (1.5% vs 25% for IV). The pivotal IRAKLIA Phase 3 trial showed comparable efficacy (ORR 71.1% SC vs 70.5% IV). The approval strengthens Sanofi's oncology franchise and could drive adoption by improving patient convenience and reducing provider burden. This follows a series of positive regulatory and pipeline updates, including recent FDA nods for Tzield and Nexviazyme. The launch trajectory and uptake in community settings will be key to watch.
At the time of this announcement, SNY was trading at $43.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $105.4B. The 52-week trading range was $40.89 to $52.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.